S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled

Bio-Techne Stock Price, News & Analysis (NASDAQ:TECH)

$62.90
-0.22 (-0.35%)
(As of 11/30/2023 ET)
Compare
Today's Range
$61.99
$63.96
50-Day Range
$52.83
$69.41
52-Week Range
$51.79
$89.91
Volume
1.45 million shs
Average Volume
1.02 million shs
Market Capitalization
$9.95 billion
P/E Ratio
41.38
Dividend Yield
0.51%
Price Target
$91.80

Bio-Techne MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
45.9% Upside
$91.80 Price Target
Short Interest
Healthy
1.83% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.37
Upright™ Environmental Score
News Sentiment
1.23mentions of Bio-Techne in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
21.47%
From $1.63 to $1.98 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.15 out of 5 stars

Medical Sector

10th out of 949 stocks

Biological Products, Except Diagnostic Industry

2nd out of 163 stocks


TECH stock logo

About Bio-Techne Stock (NASDAQ:TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Stock Price History

TECH Stock News Headlines

Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
Cystatin C Assay Market worth $540 million by 2028
Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
Bio-Techne Corp. Q1 Profit Decreases, misses estimates
Bio-Techne declares $0.08 dividend
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2024 RESULTS
Bio-Techne Q1 2024 Earnings Preview
Here's what to expect from Bio-Techne's earnings
Minneapolis-based Bio-Techne names new CEO
See More Headlines
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/1 Dividend
8/17/2023
Dividend Payable
9/01/2023
Last Earnings
10/31/2023
Ex-Dividend for 11/24 Dividend
11/09/2023
Dividend Payable
11/24/2023
Today
11/30/2023
Next Earnings (Estimated)
2/01/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
3,050
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$91.80
High Stock Price Target
$120.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+45.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$285.26 million
Pretax Margin
24.87%

Debt

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$2.57 per share
Book Value
$12.63 per share

Miscellaneous

Free Float
151,112,000
Market Cap
$9.95 billion
Optionable
Optionable
Beta
1.22

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives















TECH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TECH shares.
View TECH analyst ratings
or view top-rated stocks.

What is Bio-Techne's stock price target for 2024?

10 Wall Street research analysts have issued 12-month price objectives for Bio-Techne's stock. Their TECH share price targets range from $65.00 to $120.00. On average, they predict the company's share price to reach $91.80 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price.
View analysts price targets for TECH
or view top-rated stocks among Wall Street analysts.

How have TECH shares performed in 2023?

Bio-Techne's stock was trading at $82.88 at the start of the year. Since then, TECH shares have decreased by 24.1% and is now trading at $62.90.
View the best growth stocks for 2023 here
.

When is Bio-Techne's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our TECH earnings forecast
.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) announced its quarterly earnings data on Tuesday, October, 31st. The biotechnology company reported $0.35 EPS for the quarter, missing analysts' consensus estimates of $0.39 by $0.04. The biotechnology company had revenue of $276.94 million for the quarter, compared to analysts' expectations of $289.81 million. Bio-Techne had a trailing twelve-month return on equity of 14.89% and a net margin of 21.57%.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Tuesday, October 31st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.08 per share on Friday, November 24th. This represents a $0.32 annualized dividend and a dividend yield of 0.51%. The ex-dividend date of this dividend is Thursday, November 9th.
Read our dividend analysis for TECH
.

Is Bio-Techne a good dividend stock?

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.52%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 21.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 16.16% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

When did Bio-Techne's stock split?

Bio-Techne shares split on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were payable to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bamco Inc. NY (3.40%), Morgan Stanley (2.09%), Bank of New York Mellon Corp (1.57%), Mackenzie Financial Corp (1.47%), William Blair Investment Management LLC (1.46%) and Ameriprise Financial Inc. (1.37%). Insiders that own company stock include Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends
.

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Bio-Techne have any subsidiaries?
The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More
This page (NASDAQ:TECH) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -